References
- Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-157 https://doi.org/10.1093/qjmed/91.2.141
- Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6:488-497 https://doi.org/10.1016/j.jcmg.2012.11.013
- Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015;36:244-251 https://doi.org/10.1093/eurheartj/ehu444
- Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757 https://doi.org/10.1200/JCO.2004.03.029
- Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995 https://doi.org/10.1200/JCO.2011.38.5724
- Robbers LF, Baars EN, Brouwer WP, Beek AM, Hofman MB, Niessen HW, et al. T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging 2012;5:423-426 https://doi.org/10.1161/CIRCIMAGING.112.973438
- Kristen AV, Brokbals E, Aus dem Siepen F, Bauer R, Hein S, Aurich M, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 2016;68:13-24 https://doi.org/10.1016/j.jacc.2016.04.035
- Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson 2018;20:58
- Aus dem Siepen F, Buss SJ, Andre F, Seitz S, Giannitsis E, Steen H, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 2015;104:640-647 https://doi.org/10.1007/s00392-015-0826-3
- Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, et al. Serial native T1 mapping to monitor cardiac response to treatment in light-chain amyloidosis. Circ Cardiovasc Imaging 2016;9:e004770